Envafolimab + Regorafenib
Sources
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/40368739/
PDGFRA D842V-mutated GISTs account for about 5% to 10% of all GISTs ... Less than 1% of KIT/PDGFRA WT GISTs harbor BRAF mutations ... GISTs with NTRK gene fusions have been identified ... Other rare drivers include NF1 (somatic or germline), PIK3CA, RAS, and FGFR family translocations.
Review, Hematol Oncol Clin North Am 2025, DOI 10.1016/j.hoc.2025.04.006, PMID 40368739, text and Table 1
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06772233
A Phase II, Open-label, Multicenter, Randomized Controlled Clinical Trial Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment.
ClinicalTrials.gov API v2 record, retrieved 2026-11-07